Pharmacyte Biotech Inc (PMCB) 0.0695 $PMCB
PharmaCyte Biotech Releases New Video Highlighting Diabetes Treatment Development Program
GlobeNewswire - Tue Dec 15, 9:24AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that it has released a new video that highlights PharmaCyte's diabetes treatment development program. PharmaCyte invited Stock Market Media to sit in on its 2nd Annual International Diabetes Consortium in Vienna, Austria, to document PharmaCyte's story related to the development of its treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes.
PharmaCyte Biotech Provides Update on Malignant Ascites and New Colon Cancer Studies
GlobeNewswire - Mon Dec 07, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today issued an update on the preclinical studies that are designed to determine the effectiveness of the Cell-in-a-Box plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors. Each of the preclinical studies in ascites are being conducted by Translational Drug Development (TD2) - the premier CRO in the United States specializing in oncology. TD2 is also the CRO conducting PharmaCyte's upcoming clinical trial in advanced pancreatic cancer.
PharmaCyte Contractor Chamow & Associates to Visit Cell-in-a-Box(R) Encapsulation Facility in Bangkok, Thailand
GlobeNewswire - Fri Dec 04, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that representatives from Chamow & Associates, the San Francisco Bay Area firm contracted to assist PharmaCyte in preparing the Chemistry, Manufacturing and Controls (CMC) section of the Investigational New Drug Application (IND) that will be submitted to the drug regulatory authorities before commencement of PharmaCyte's pancreatic cancer clinical trial, will visit the Austrianova Cell-in-a-Boxencapsulation facility next week located in Bangkok, Thailand.
PharmaCyte Biotech Provides Link to Orphan Drug Designation for Its Pancreatic Cancer Treatment
GlobeNewswire - Tue Nov 24, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that the European Commission has updated its website to reflect that PharmaCyte Biotech Europe Limited, a subsidiary of PharmaCyte Biotech, Inc., is the "sponsor" or holder of the Orphan Drug designation in Europe for PharmaCyte's pancreatic cancer treatment.
A Look Inside the Chart, Technical Insights - Research on LivePerson, Pharmacyte Biotech, Agenus, and Straight Path Communications
ACCESSWIRE - Tue Nov 24, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: LivePerson Inc (NASDAQ: LPSN), Pharmacyte Biotech Inc (OTC: PMCB), Agenus Inc (NASDAQ: AGEN) and Straight Path Communications Inc (NYSE: STRP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AGEN: 4.50 (-0.05), STRP: 17.02 (+0.30), LPSN: 7.25 (-0.07)
PharmaCyte Biotech Announces Appointment of International Diabetes Expert to Scientific Advisory Board
GlobeNewswire - Thu Nov 19, 9:40AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Prof. Hans-Peter Hammes, M.D., has accepted an appointment to PharmaCyte's Scientific Advisory Board. Prof. Hammes is recognized internationally as a preeminent figure in the treatment of diabetes and its complications. In addition to his appointment to the Board, Prof. Hammes has agreed to become a member of PharmaCyte's international Diabetes Consortium and to serve as a consultant to PharmaCyte.
PharmaCyte Biotech Appoints International Diabetes Expert to Its Scientific Advisory Board
GlobeNewswire - Thu Nov 19, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Prof. Hans-Peter Hammes, M.D., has accepted an appointment to PharmaCyte's Scientific Advisory Board. Prof. Hammes is recognized internationally as a preeminent figure in the treatment of diabetes and its complications. In addition to his appointment to the Board, Prof. Hammes has agreed to become a member of PharmaCyte's international Diabetes Consortium and to serve as a consultant to PharmaCyte.
PharmaCyte Biotech Obtains Orphan Drug Designation in Europe for Its Pancreatic Cancer Treatment
GlobeNewswire - Tue Nov 17, 8:22AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that, upon the recommendation of the European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation to PharmaCyte's subsidiary, PharmaCyte Biotech Europe Limited, for PharmaCyte's pancreatic cancer treatment. Receiving Orphan Drug designation for PharmaCyte's pancreatic cancer treatment carries with it 10 years of marketing exclusivity in countries in the European Union. In addition, the EMA provides special assistance in the development of PharmaCyte's treatment for pancreatic cancer.
A Look Inside the Chart, Technical Insights - Research on Student Transportation, Medical Marijuana, NanoTech Entertainment and Pharmacyte Biotech
ACCESSWIRE - Mon Nov 16, 7:15AM CST
NEW YORK, NY / ACCESSWIRE / November 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Student Transportation Inc (NASDAQ: STB),Medical Marijuana Inc (OTC: MJNA), NanoTech Entertainment Inc (OTC: NTEK) and Pharmacyte Biotech Inc (OTC: PMCB). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
STB: 3.53 (-0.05)
Broad Street Alerts - PharmaCyte Biotech Investor Update: Revolutionizing Potential Diabetes Treatment
PR Newswire - Thu Nov 12, 7:21AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.10 off 2.54% in yesterday's session. Trading volume was 1.3 million shares, near the daily average of 1.7 million shares traded.
PharmaCyte Biotech Scientific Advisory Board Member Named Clinical Director of Prestigious Boston Cancer Center
GlobeNewswire - Tue Nov 10, 9:17AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Manuel Hidalgo, MD, PhD, an internationally respected oncologist and a member of PharmaCyte 's Scientific Advisory Board, has been named Clinical Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center, part of the Cancer Center at the Beth Israel Deaconess Medical Center (BIDMC) in Boston. Dr. Hidalgo has also been appointed Chief of the hospital's Division of Hematology-Oncology. In his role at the prestigious medical center, Dr. Hidalgo will oversee all of BIDMC's clinical cancer programs.
Equities Lead Investor Sentiment - Research on Elite Pharmaceuticals, Medical Marijuana, Ekso Bionics Holdings and Pharmacyte Biotech
ACCESSWIRE - Mon Nov 09, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / November 9, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Elite Pharmaceuticals Inc (OTC: ELTP),Medical Marijuana Inc (PINKSHEETS: MJNA), Ekso Bionics Holdings Inc (OTC: EKSO) and Pharmacyte Biotech Inc (OTC: PMCB). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Direction of Market Influences - Research on Pharmacyte Biotech, NuGene International, Rainbow Coral Corp and Elite Pharmaceuticals
ACCESSWIRE - Mon Nov 02, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / November 2, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Pharmacyte Biotech Inc (OTC: PMCB), NuGene International Inc (OTC: NUGN), Rainbow Coral Corp (OTC: RBCC) and Elite Pharmaceuticals Inc (OTC: ELTP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.
PharmaCyte Biotech Hosts 2nd Annual Meeting of International Diabetes Consortium Developing Novel Treatment for Diabetes
GlobeNewswire - Thu Oct 29, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that PharmaCyte held the second annual meeting of its "International Diabetes Consortium" in Vienna, Austria, to review data that has been generated by the Consortium and update its strategic plan for the development of PharmaCyte's treatment for insulin dependent diabetes.
Quantified Self: MyDx Targets a Growing Multi-Billion Dollar Industry
ACCESSWIRE - Tue Oct 27, 8:24AM CDT
SEATTLE, WA / ACCESSWIRE / October 27, 2015 / The quantified self movement has been rapidly expanding over the past several years, as consumers embrace its "if you can measure it, you can change it" principles. According to IHS, the global market for wearables and sensors will rise to 210 million units shipped and $30 billion in revenue by 2018, while companies like FitBit Inc. (NYSE: FIT) and Apple Inc. (NASDAQ: AAPL) are already making millions of dollars each quarter selling early-stage technology.
FIT: 27.73 (-0.08), ABT: 43.70 (-1.56), GWPH: 66.79 (-1.90), AAPL: 106.03 (-2.95)
PharmaCyte Biotech Due Diligence Report - Technology Gets an Industry Boost - Small Cap Street
PR Newswire - Tue Oct 27, 7:15AM CDT
PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.10 off 5.66% in yesterday's session. Trading volume was 3 million shares, somewhat over the daily average of 2 million shares traded. PMCB shares had jumped 75% from mid-September to mid-October before investors took some profits over the past two weeks.
PharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial Design
GlobeNewswire - Fri Oct 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the release of a recorded interview with Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree that highlights the key aspects of PharmaCyte's new pancreatic cancer clinical trial design.
A Look Behind the Curtain - Research on PetroTerra, Kirin International Holdings, Force Protection Video Equipment, Black Stallion Oil & Gas, and PharmaCyte Biotech
ACCESSWIRE - Thu Oct 22, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 22, 2015 / Moments ago, ACI Association released new research updates concerning several important developing situations including the following equities: Petroterra Corp (OTC: PTRA), Kirin International Holding Inc. (OTC: KIRI), Force Protection Video Equipment Corp (OTC: FPVD), Black Stallion Oil and Gas Inc. (OTC: BLKG), and Pharmacyte Biotech Inc. (OTC: PMCB). ACI Association provides a single unified platform for investors to hear about what matters. The full research reports are being made available to the public on a complimentary basis.
PharmaCyte Biotech Clinical Trial Designed to Expand Standard of Care Therapy for Pancreatic Cancer
GlobeNewswire - Wed Oct 21, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the new trial design for its upcoming clinical trial in patients with advanced pancreatic cancer using PharmaCyte's treatment (Cell-in-a-Box+ low-dose ifosfamide chemotherapy).
PharmaCyte Biotech's Cell Encapsulation Technology at the Forefront of Future Diabetes Treatments
PR Newswire - Tue Oct 20, 8:15AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit http://www.GoldmanResearch.com.
PharmaCyte Biotech Releases New Video Highlighting Diabetes Treatment Development Program
GlobeNewswire - Tue Dec 15, 9:24AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that it has released a new video that highlights PharmaCyte's diabetes treatment development program. PharmaCyte invited Stock Market Media to sit in on its 2nd Annual International Diabetes Consortium in Vienna, Austria, to document PharmaCyte's story related to the development of its treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte Biotech Provides Update on Malignant Ascites and New Colon Cancer Studies
GlobeNewswire - Mon Dec 07, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today issued an update on the preclinical studies that are designed to determine the effectiveness of the Cell-in-a-Box plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors. Each of the preclinical studies in ascites are being conducted by Translational Drug Development (TD2) - the premier CRO in the United States specializing in oncology. TD2 is also the CRO conducting PharmaCyte's upcoming clinical trial in advanced pancreatic cancer. PharmaCyte Contractor Chamow & Associates to Visit Cell-in-a-Box(R) Encapsulation Facility in Bangkok, Thailand
GlobeNewswire - Fri Dec 04, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that representatives from Chamow & Associates, the San Francisco Bay Area firm contracted to assist PharmaCyte in preparing the Chemistry, Manufacturing and Controls (CMC) section of the Investigational New Drug Application (IND) that will be submitted to the drug regulatory authorities before commencement of PharmaCyte's pancreatic cancer clinical trial, will visit the Austrianova Cell-in-a-Boxencapsulation facility next week located in Bangkok, Thailand. PharmaCyte Biotech Provides Link to Orphan Drug Designation for Its Pancreatic Cancer Treatment
GlobeNewswire - Tue Nov 24, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that the European Commission has updated its website to reflect that PharmaCyte Biotech Europe Limited, a subsidiary of PharmaCyte Biotech, Inc., is the "sponsor" or holder of the Orphan Drug designation in Europe for PharmaCyte's pancreatic cancer treatment. A Look Inside the Chart, Technical Insights - Research on LivePerson, Pharmacyte Biotech, Agenus, and Straight Path Communications
ACCESSWIRE - Tue Nov 24, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: LivePerson Inc (NASDAQ: LPSN), Pharmacyte Biotech Inc (OTC: PMCB), Agenus Inc (NASDAQ: AGEN) and Straight Path Communications Inc (NYSE: STRP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AGEN: 4.50 (-0.05), STRP: 17.02 (+0.30), LPSN: 7.25 (-0.07)
PharmaCyte Biotech Announces Appointment of International Diabetes Expert to Scientific Advisory Board
GlobeNewswire - Thu Nov 19, 9:40AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Prof. Hans-Peter Hammes, M.D., has accepted an appointment to PharmaCyte's Scientific Advisory Board. Prof. Hammes is recognized internationally as a preeminent figure in the treatment of diabetes and its complications. In addition to his appointment to the Board, Prof. Hammes has agreed to become a member of PharmaCyte's international Diabetes Consortium and to serve as a consultant to PharmaCyte. PharmaCyte Biotech Appoints International Diabetes Expert to Its Scientific Advisory Board
GlobeNewswire - Thu Nov 19, 8:25AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Prof. Hans-Peter Hammes, M.D., has accepted an appointment to PharmaCyte's Scientific Advisory Board. Prof. Hammes is recognized internationally as a preeminent figure in the treatment of diabetes and its complications. In addition to his appointment to the Board, Prof. Hammes has agreed to become a member of PharmaCyte's international Diabetes Consortium and to serve as a consultant to PharmaCyte. PharmaCyte Biotech Obtains Orphan Drug Designation in Europe for Its Pancreatic Cancer Treatment
GlobeNewswire - Tue Nov 17, 8:22AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that, upon the recommendation of the European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation to PharmaCyte's subsidiary, PharmaCyte Biotech Europe Limited, for PharmaCyte's pancreatic cancer treatment. Receiving Orphan Drug designation for PharmaCyte's pancreatic cancer treatment carries with it 10 years of marketing exclusivity in countries in the European Union. In addition, the EMA provides special assistance in the development of PharmaCyte's treatment for pancreatic cancer. A Look Inside the Chart, Technical Insights - Research on Student Transportation, Medical Marijuana, NanoTech Entertainment and Pharmacyte Biotech
ACCESSWIRE - Mon Nov 16, 7:15AM CST
NEW YORK, NY / ACCESSWIRE / November 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Student Transportation Inc (NASDAQ: STB),Medical Marijuana Inc (OTC: MJNA), NanoTech Entertainment Inc (OTC: NTEK) and Pharmacyte Biotech Inc (OTC: PMCB). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
STB: 3.53 (-0.05)
Broad Street Alerts - PharmaCyte Biotech Investor Update: Revolutionizing Potential Diabetes Treatment
PR Newswire - Thu Nov 12, 7:21AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.10 off 2.54% in yesterday's session. Trading volume was 1.3 million shares, near the daily average of 1.7 million shares traded.
PharmaCyte Biotech Scientific Advisory Board Member Named Clinical Director of Prestigious Boston Cancer Center
GlobeNewswire - Tue Nov 10, 9:17AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Manuel Hidalgo, MD, PhD, an internationally respected oncologist and a member of PharmaCyte 's Scientific Advisory Board, has been named Clinical Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center, part of the Cancer Center at the Beth Israel Deaconess Medical Center (BIDMC) in Boston. Dr. Hidalgo has also been appointed Chief of the hospital's Division of Hematology-Oncology. In his role at the prestigious medical center, Dr. Hidalgo will oversee all of BIDMC's clinical cancer programs. Equities Lead Investor Sentiment - Research on Elite Pharmaceuticals, Medical Marijuana, Ekso Bionics Holdings and Pharmacyte Biotech
ACCESSWIRE - Mon Nov 09, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / November 9, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Elite Pharmaceuticals Inc (OTC: ELTP),Medical Marijuana Inc (PINKSHEETS: MJNA), Ekso Bionics Holdings Inc (OTC: EKSO) and Pharmacyte Biotech Inc (OTC: PMCB). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Direction of Market Influences - Research on Pharmacyte Biotech, NuGene International, Rainbow Coral Corp and Elite Pharmaceuticals
ACCESSWIRE - Mon Nov 02, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / November 2, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Pharmacyte Biotech Inc (OTC: PMCB), NuGene International Inc (OTC: NUGN), Rainbow Coral Corp (OTC: RBCC) and Elite Pharmaceuticals Inc (OTC: ELTP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.
PharmaCyte Biotech Hosts 2nd Annual Meeting of International Diabetes Consortium Developing Novel Treatment for Diabetes
GlobeNewswire - Thu Oct 29, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that PharmaCyte held the second annual meeting of its "International Diabetes Consortium" in Vienna, Austria, to review data that has been generated by the Consortium and update its strategic plan for the development of PharmaCyte's treatment for insulin dependent diabetes. Quantified Self: MyDx Targets a Growing Multi-Billion Dollar Industry
ACCESSWIRE - Tue Oct 27, 8:24AM CDT
SEATTLE, WA / ACCESSWIRE / October 27, 2015 / The quantified self movement has been rapidly expanding over the past several years, as consumers embrace its "if you can measure it, you can change it" principles. According to IHS, the global market for wearables and sensors will rise to 210 million units shipped and $30 billion in revenue by 2018, while companies like FitBit Inc. (NYSE: FIT) and Apple Inc. (NASDAQ: AAPL) are already making millions of dollars each quarter selling early-stage technology.
FIT: 27.73 (-0.08), ABT: 43.70 (-1.56), GWPH: 66.79 (-1.90), AAPL: 106.03 (-2.95)
PharmaCyte Biotech Due Diligence Report - Technology Gets an Industry Boost - Small Cap Street
PR Newswire - Tue Oct 27, 7:15AM CDT
PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.10 off 5.66% in yesterday's session. Trading volume was 3 million shares, somewhat over the daily average of 2 million shares traded. PMCB shares had jumped 75% from mid-September to mid-October before investors took some profits over the past two weeks.
PharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial Design
GlobeNewswire - Fri Oct 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the release of a recorded interview with Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree that highlights the key aspects of PharmaCyte's new pancreatic cancer clinical trial design. A Look Behind the Curtain - Research on PetroTerra, Kirin International Holdings, Force Protection Video Equipment, Black Stallion Oil & Gas, and PharmaCyte Biotech
ACCESSWIRE - Thu Oct 22, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 22, 2015 / Moments ago, ACI Association released new research updates concerning several important developing situations including the following equities: Petroterra Corp (OTC: PTRA), Kirin International Holding Inc. (OTC: KIRI), Force Protection Video Equipment Corp (OTC: FPVD), Black Stallion Oil and Gas Inc. (OTC: BLKG), and Pharmacyte Biotech Inc. (OTC: PMCB). ACI Association provides a single unified platform for investors to hear about what matters. The full research reports are being made available to the public on a complimentary basis.
PharmaCyte Biotech Clinical Trial Designed to Expand Standard of Care Therapy for Pancreatic Cancer
GlobeNewswire - Wed Oct 21, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the new trial design for its upcoming clinical trial in patients with advanced pancreatic cancer using PharmaCyte's treatment (Cell-in-a-Box+ low-dose ifosfamide chemotherapy). PharmaCyte Biotech's Cell Encapsulation Technology at the Forefront of Future Diabetes Treatments
PR Newswire - Tue Oct 20, 8:15AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit http://www.GoldmanResearch.com.
